ArticleFuture oncology (London, England)2024
Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices.
Adam Brufsky et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it